Rituximab maintenance in elderly patients with follicular lymphoma

Follicular lymphoma (FL) is a chronic, indolent lymphoid malignancy and represents the most common slow growing lymphoma in the United States and Europe1. Patients with FL experience generally favorable outcomes with median overall survival (OS) lasting close to 18 years2. Improvements in FL survival have occurred consistently over the past several years, and for symptomatic patients treated with chemoimmunotherapy, durable disease control is achievable, lasting several years. Chemo-immunotherapy with antiCD20 antibody rituximab has changed the treatment landscape of FL by improving response rates and progression free survival (PFS).
Source: Leukemia Research - Category: Hematology Authors: Source Type: research